MBQ-Pharma targets Rac and CDC42 as key targets for tumor growth inhibition and removal of pre-existing metastasis. MBQ-167 is a first-in-class nanomolar IC50 inhibitor for Rac and CDC42 and has been shown in mouse tumor models to inhibit tumor growth and to reverse advanced metastasis. MBQ-167 has also been shown to have no toxicity findings in rats and dogs through GLP studies and in Safety Pharmacology studies. The IND for MBQ-167 is scheduled by the end of 2021.